Loading clinical trials...
Loading clinical trials...
A Phase 1, Double-blind, Placebo-controlled, Randomized Study of the Safety, Tolerability, and Pharmacokinetics of BMS-986419 (Part 1) and a Phase 1 Randomized, Double-blind, Positive-controlled, Placebo-controlled, Parallel, Nested-crossover (Moxifloxacin-placebo) Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants
Conditions
Interventions
BMS-986419
BMS-986419 Matching Placebo
+2 more
Locations
1
United States
Celerion
Tempe, Arizona, United States
Start Date
February 27, 2025
Primary Completion Date
October 21, 2025
Completion Date
October 21, 2025
Last Updated
November 17, 2025
NCT07310264
NCT06342713
NCT07472361
NCT06649110
NCT06823947
NCT07240675
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions